Therefore, we considered these features very interesting, and propose Ageritin as an adjuvant substance for the treatment of glioblastoma on several fronts: on the one hand, the genotoxicity of Ageritin is similar to many anti-cancer drugs; on the other hand, it inhibits TNFR1, which directs the control of the life and death balance in a cell. Here, TNFRSF1A is linked to glioblastoma.